Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia

Jovanović, Jelena; Score, Joannah; Waghorn, Katherine; Cilloni, Daniela; Gottardi, Enrico; Metzgeroth, Georgia; Erben, Philipp; Popp, Helena; Walz, Christoph; Hochhaus, Andreas; Roche‐Lestienne, Catherine; Preudhomme, Claude; Solomon, Ellen; Apperley, Jane F.; Rondoni, Michela; Ottaviani, Emanuela; Brito‐Babapulle, Finella; Saglio, Giuseppe; Hehlmann, Rüdiger; Cross, Nicholas C. P.; Reiter, Andreas; Grimwade, David

doi:10.1182/blood-2006-10-050054

Cited by 198 publications

(208 citation statements)

References 25 publications

(48 reference statements)

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…57,58 The response to imatinib is typically within days to a few weeks, and complete hematologic and molecular remission is almost universal. 7,[58][59][60][61][62] Whereas maintenance of remission has been reported with imatinib doses as low as 100 mg weekly, 63 daily dosing seems more prudent due to the theoretical risk of inducing resistance. Although early studies demonstrated relapse in all PDGFRA-positive patients within 2 to 3 months of imatinib discontinuation, 64 recent data suggests that cure may be possible in some cases, especially after prolonged molecular remission.…”

Section: Pdgfr-associated Mpnmentioning

confidence: 99%

How I treat hypereosinophilic syndromes

Klion

2015

Blood

199

126

View full text Add to dashboard Cite

Hypereosinophilic syndromes (HESs) are a group of rare disorders characterized by peripheral blood eosinophilia of 1.5 × 109/L or higher and evidence of end organ manifestations attributable to the eosinophilia and not otherwise explained in the clinical setting. HESs are pleomorphic in clinical presentation and can be idiopathic or associated with a variety of underlying conditions, including allergic, rheumatologic, infectious, and neoplastic disorders. Moreover, the etiology of the eosinophilia in HESs can be primary (myeloid), secondary (lymphocyte-driven), or unknown. Although corticosteroids remain the first-line therapy for most forms of HESs, the availability of an increasing number of novel therapeutic agents, including tyrosine kinase inhibitors and monoclonal antibodies, has necessarily altered the approach to treatment of HESs. This review presents an updated treatment-based approach to the classification of patients with presumed HES and discusses the roles of conventional and novel agents in the management of these patients.

show abstract

Section: Pdgfr-associated Mpnmentioning

confidence: 99%

How I treat hypereosinophilic syndromes

Klion

2015

Blood

199

126

View full text Add to dashboard Cite

show abstract

“…Similarly, the fusion was found in only 40 of 376 individuals (11%) in a European trial of patients with persistent, unexplained hypereosinophilia. 10 In a Mayo series, 11 of 89 patients (12%) with moderateto-severe eosinophilia were FIP1L1-PDGFRA positive. 11 In a follow-up series of 714 unselected patients with eosinophilia, only 3% were fusion positive.…”

Section: Terminology and Classificationmentioning

confidence: 99%

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

Gotlib¹,

2008

View full text Add to dashboard Cite

“…Asimismo, en otra serie de 40 pacientes, se reportó remisión hematológica por más de un año, aún en aquéllos tratados con 100 mg/día de imatinib. Esto traduce una mayor sensibilidad general que LMC al tratamiento con ITK de primera línea 9,13 . En relación a la duración del tratamiento, se recomienda que éste sea permanente y en la dosis a la cual se haya producido respuesta.…”

Section: Discussionunclassified

Leucemia eosinofílica crónica con respuesta hematológica sostenida tras tratamiento con bajas dosis de imatinib

Chandía

2014

Rev. méd. Chile

View full text Add to dashboard Cite

Fax: 56-71-413657 demetriotorresc@gmail.com L a eosinofilia en sangre o tejidos puede ser producida por una gran variedad de situaciones clínicas: desde cuadros autolimitados hasta enfermedades de riesgo vital. La gravedad de las manifestaciones clínicas está directamente relacionada con el tiempo de exposición y magnitud del recuento de eosinófilos. El término hipereosinofilia se refiere a recuentos sostenidos de eosinófilos superiores a 1.500/mL en sangre periférica, los que pueden producir daño e infiltración en órganos diana independiente de la causa que lo provoque 1 .El término leucemia eosinofílica crónica (CEL) alude a un subgrupo de neoplasias mieloproliferativas, caracterizada por hipereosinofilia en médula ósea y sangre periférica; asociada a variable compromiso de mastocitos y neutrófilos. En su forma pura, es secundaria a alteraciones cromosómicas.De ellas, la más frecuente, es la ocasionada por el reordenamiento 4q12 que origina el producto de fusión FIP1L1/PDGFRA. Otras causas menos frecuentes son los reordenamientos en los genes PDGFRB y FGFR1, asociándose también este último a neoplasias linfoides 2-4 . A la fecha no existen reportes de su prevalencia en Chile y el subdiagnóstico dificulta la estimación de su real presencia en la población.Se presenta el caso de un paciente con CEL asociada a reordenamiento de PDGFRA, con rápi-da y sostenida respuesta a inhibidores de tirosina quinasa (ITK). Caso clínicoPaciente 58 años de edad, sexo masculino, previamente sano, sin antecedente de uso de medica-

show abstract

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia

Cited by 198 publications

References 25 publications

How I treat hypereosinophilic syndromes

How I treat hypereosinophilic syndromes

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

Leucemia eosinofílica crónica con respuesta hematológica sostenida tras tratamiento con bajas dosis de imatinib

Contact Info

Product

Resources

About